Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration (SAXA)

This study has been completed.
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 12, 2012
Last updated: December 12, 2013
Last verified: December 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)